Brief: Ose Immunotherapeutics Presented First Positive Results Data On ON CLEC-1
15/11/2021 06:42
Nov 15 (Reuters) - Ose Immunotherapeutics SA OSE.PA :
* OSE IMMUNOTHERAPEUTICS PRESENTED THE FIRST POSITIVE
PRECLINICAL
EFFICACY DATA ON CLEC-1, A NOVEL MYELOID IMMUNE CHECKPOINT
TARGET FOR CANCER IMMUNOTHERAPY
Source text for Eikon: ID:nBw2Tnr4ya
Further company coverage: OSE.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO